C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1)
© 2021 Walter de Gruyter GmbH, Berlin/Boston..
Strategies to sensitize hepatocellular carcinomas (HCC) to programmed death-1 (PD1)/programmed death-ligand 1 (PD-L1) inhibitor therapies are important in improving the survival of HCC patients. The aim of the study was to characterize C-X-C chemokine receptor 2 (Cxcr2) as a therapeutic target in HCC and evaluate the effects of Cxcr2 suppression in sensitizing HCC to PD1/PD-L1 inhibitor therapies. To this end, we constructed a Cxcr2-knockout HCC cell line (Hepa1-6 KO) using the CRISPR-Cas9 approach and assessed the tumor growth rate and survival of mice after subcutaneously inoculating Hepa1-6 KO cells in mice. We show that Cxcr2 knockdown does not dramatically inhibit tumor growth and improve mouse survival. In tumor xenografts, the proportion of T cells is not affected but the ratio of M1/M2 macrophage is greatly increased. Cxcr2 knockdown does not alter cell viability but macrophages co-cultured with Hepa1-6 KO cells are shifted to M1 phenotypes compared to WT cells. Hepa-1-6 KO cells exhibit lower levels of PD-L1 expression. c-Myc is suppressed in Hepa1-6 KO cells, which contributes to PD-L1 downregulation. Knockdown of Cxcr2 decreases PD-L1 levels and consequently promotes the shift of macrophages to the M1 phenotype, which is mediated by downregulating c-Myc. In summary, Cxcr2 is a potential target for suppressing immune escape in HCC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:402 |
---|---|
Enthalten in: |
Biological chemistry - 402(2021), 6 vom: 26. Mai, Seite 729-737 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wan, Yafeng [VerfasserIn] |
---|
Links: |
---|
Themen: |
B7-H1 Antigen |
---|
Anmerkungen: |
Date Completed 12.11.2021 Date Revised 12.11.2021 published: Electronic-Print Citation Status MEDLINE |
---|
doi: |
10.1515/hsz-2020-0328 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321427971 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321427971 | ||
003 | DE-627 | ||
005 | 20231225175803.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1515/hsz-2020-0328 |2 doi | |
028 | 5 | 2 | |a pubmed24n1071.xml |
035 | |a (DE-627)NLM321427971 | ||
035 | |a (NLM)33583159 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wan, Yafeng |e verfasserin |4 aut | |
245 | 1 | 0 | |a C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1) |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 12.11.2021 | ||
500 | |a Date Revised 12.11.2021 | ||
500 | |a published: Electronic-Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 Walter de Gruyter GmbH, Berlin/Boston. | ||
520 | |a Strategies to sensitize hepatocellular carcinomas (HCC) to programmed death-1 (PD1)/programmed death-ligand 1 (PD-L1) inhibitor therapies are important in improving the survival of HCC patients. The aim of the study was to characterize C-X-C chemokine receptor 2 (Cxcr2) as a therapeutic target in HCC and evaluate the effects of Cxcr2 suppression in sensitizing HCC to PD1/PD-L1 inhibitor therapies. To this end, we constructed a Cxcr2-knockout HCC cell line (Hepa1-6 KO) using the CRISPR-Cas9 approach and assessed the tumor growth rate and survival of mice after subcutaneously inoculating Hepa1-6 KO cells in mice. We show that Cxcr2 knockdown does not dramatically inhibit tumor growth and improve mouse survival. In tumor xenografts, the proportion of T cells is not affected but the ratio of M1/M2 macrophage is greatly increased. Cxcr2 knockdown does not alter cell viability but macrophages co-cultured with Hepa1-6 KO cells are shifted to M1 phenotypes compared to WT cells. Hepa-1-6 KO cells exhibit lower levels of PD-L1 expression. c-Myc is suppressed in Hepa1-6 KO cells, which contributes to PD-L1 downregulation. Knockdown of Cxcr2 decreases PD-L1 levels and consequently promotes the shift of macrophages to the M1 phenotype, which is mediated by downregulating c-Myc. In summary, Cxcr2 is a potential target for suppressing immune escape in HCC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a CXCL8 | |
650 | 4 | |a Cxcr2 | |
650 | 4 | |a PD-L1 | |
650 | 4 | |a c-Myc | |
650 | 4 | |a hepatocellular carcinoma | |
650 | 4 | |a immune escape | |
650 | 7 | |a B7-H1 Antigen |2 NLM | |
650 | 7 | |a CD274 protein, human |2 NLM | |
650 | 7 | |a CXCR2 protein, human |2 NLM | |
650 | 7 | |a Receptors, Interleukin-8B |2 NLM | |
700 | 1 | |a Ge, Ke |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Weijiang |e verfasserin |4 aut | |
700 | 1 | |a Lu, Jun |e verfasserin |4 aut | |
700 | 1 | |a Jia, Changku |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Hanzhang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biological chemistry |d 1997 |g 402(2021), 6 vom: 26. Mai, Seite 729-737 |w (DE-627)NLM088892875 |x 1437-4315 |7 nnns |
773 | 1 | 8 | |g volume:402 |g year:2021 |g number:6 |g day:26 |g month:05 |g pages:729-737 |
856 | 4 | 0 | |u http://dx.doi.org/10.1515/hsz-2020-0328 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 402 |j 2021 |e 6 |b 26 |c 05 |h 729-737 |